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Abstract

Introduction

Results
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Tubulointerstitial fibrosis is by far one of the most
common pathological hallmarks associated with
cyclosporine (CsA) induced nephrotoxicity. Here we map
the effects of altered microRNA (miR) expression levels on
the TGFβ pathway in response to CsA treatment. Based on
literature reviewed and the microarray data gathered by
Gooch et al (publication in progress), we hypothesize that
CsA alters the expression of renal miRs and that the altered
expression of the miRs has implications in renal fibrosis that
can be mapped out through the use of both in vivo and in
vitro models. We predict that HEK 293 cells can be used as
an in vitro model for comparison to the microarray data
obtained by Gooch et al. We hope to show through parallel
experiments, in mice renal tissue and HEK 293 cells, the
usefulness of HEK 293 cells as an in vitro tool for the study
of CsA-induced renal fibrosis.
Through the use of q-rtPCR, we first validated the results
obtained in a microarray study which demonstrated that
certain miRs exhibit altered expression in response to CsA
treatment in kidney tissues isolated from mice. Next, we
looked at the use of HEK 293 cells as a proposed model for
in vitro study of CsA regulated miRs in renal fibrosis.
Finally we map changes in mRNA levels for some projected
targets of the miRs shown to control various aspects of the
TGFβ pathway. This complete work provides new insights
into the involvement of miRs as regulators of the TGFβ
pathway as well as demonstrates the usefulness of HEK 293
cells as an in vitro model that can be used for further study
of CsA induced renal fibrosis.

Tubulointerstitial fibrosis is one of the most common
pathological hallmarks of chronic kidney disease and many
other end stage renal diseases. Fibrosis as a result of drug
treatment programs like the administration of CsA to organ
transplant recipients is of special to our team because there are
certain considerations we can take into account for its cause,
specifically the role of microRNAs in the progression of the
disease state [1,2]. CsA is an immunosuppressant which works
by inhibiting the dephosphorylation of cytosolic NFAT in the T
cell preventing an immune response from occurring [3]. At the
same time CsA also works to increase the levels of active
TGFβ inside the cell, this action is what leads to the fibrotic
effect seen in CsA patients [4]. TGFβ is involved in the
production of ECM components, and an increase in its activity
is directly related to renal fibrosis [4-7]. The TGFβ pathway has
effects on numerous mRNAs and these alterations are believed
to be a major cause of the fibrotic process [8-11]. One of the
ways in which TGFβ may cause these alterations is through the
involvement of microRNAs (miRs). miRs work by regulating the
rate of transcription and translation of mRNAs and proteins.
Our belief is that in response to CsA treatment the level of miR
expression becomes altered, and this change in miR
expression plays a vital role into the regulation of CsA induced
renal fibrosis through modulation of the TGFβ pathway. Herein
we show both in vivo (mice renal tissues) and in vitro models
(HEK 293 cells) of miR alteration and mRNA changes involved
in CsA treatment and CsA induced renal fibrosis.

Through conducting the study we were able to validate the microarray findings for miR 21
and miR 186 in the mice renal tissues. We conclude from this information the both of these miRs
are most likely upregulated in response to CsA treatment. For miR 709 our in vivo findings appear
to contradict the array data and more study needs to be preformed to look at this specific miR. The
mRNAs in the in vivo model show no significant regulation. In the in vitro HEK 293 cell model none
of the miRs examined had any significant amount of regulation. The in vitro mRNA study did show
a significant amount of up regulation for all mRNAs examined in response to CsA treatment. In the
time response experiment for the miRs we discovered that there appears to be an initial increase
in miR expression for miRs 21 and 186, and that expression decreases with time. miR 709 had no
significant time response in expression.

The findings of this work help to validate the
microarray data previously obtained by our lab, as well
as show the usefulness of the HEK 293 cell as an in vitro
model in the study of CsA induced renal fibrosis. Based
on the information gathered in this study we conclude
that is is worthwhile to continue looking at the role miRs
play in CsA induced renal fibrosis, and plan to continue
to examine the HEK 293 cell as an in vitro model for this
purpose. The information gathered herein helps to
expand the knowledge of miR regulation on mRNAs and
helps to grow the limited amount of knowledge on miR
involvement in the fibrotic process. Based on this study
we plan to examine more miRs and mRNAs and
eventually plan to use miR mimics and anti-miR
technology to gather a fuller understanding of miRs in
the process of renal fibrosis. Doing this would contribute
to our overall goal of developing a pharmaceutical agent
of some from that could be administered to patients
receiving CsA to prevent fibrosis from occurring without
altering the immunosuppressive activity of the drug.
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Project Goals
1.

Hypothesis:
CsA treatment leads to alterations in miR
expression levels and, subsequently, changes in
mRNAs that lead to the process of renal fibrosis.
Goal 1: Validation of microarray
Specific Aim 1: Validation of microarray data obtained
by Gooch et al. showing the alterations in miR
expression in mouse renal tissue
Goal 2: Show usefulness of HEK 293 cells an in vitro
model of
renal fibrosis
Specific Aim 2: Show parallel changes in miRs
between in vitro and in vivo models
Specific Aim 3: Show parallel changes in mRNA in in
vivo and in vitro models

Methods
The methods utilized for this project included cell culture
of HEK 293 cells, treatment of the cell cultures with CsA,
harvesting of total RNA from archived mice renal tissue as well
as from the CsA treated HEK 293 cells. MTT viability assays
were conducted to determine the LD50 for CsA on the HEK 293
cell cultures, and q-rtPCR was used to evaluate the expression
of renal miRs and mRNAs in both control and CsA treated
groups. The ΔΔCT method was used to analyze the q-rtPCR
results and statistical significance was calculated through the
use of T Test and post Hoc ANOVA.
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